TY - JOUR
T1 - Targeting the bone marrow microenvironment in hematologic malignancies
AU - Dalton, William S.
AU - Hazlehurst, Lori
AU - Shain, Kenneth
AU - Landowski, Terry
AU - Alsina, Melissa
N1 - Funding Information: Supported by Grants No. CA 82533 and CA77859 and by the Multiple Myeloma Research Foundation (W.S.D.).
PY - 2004/4
Y1 - 2004/4
N2 - Unicellular drug-resistant models have been critical in elucidating intrinsic drug-resistant mechanisms; however, these models do not consider resistance mechanisms that may be elicited by extrinsic influences such as the tumor microenvironment. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumor cells to evade or circumvent drug-induced death and that this may represent a form of de novo drug resistance. We have found that elements of the bone marrow microenvironment, including extracellular matrices and normal stromal elements, protect malignant cells, including leukemia and myeloma cells, from drug-induced cell death. This extrinsic form of drug resistance may allow cells to survive initial drug treatment and thereby acquire a more complex, intrinsic drug-resistant phenotype. Focusing on this form of do novo drug resistance may ultimately prevent the emergence of acquired drug resistance and enhance drug therapy for hematologic malignancies.
AB - Unicellular drug-resistant models have been critical in elucidating intrinsic drug-resistant mechanisms; however, these models do not consider resistance mechanisms that may be elicited by extrinsic influences such as the tumor microenvironment. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumor cells to evade or circumvent drug-induced death and that this may represent a form of de novo drug resistance. We have found that elements of the bone marrow microenvironment, including extracellular matrices and normal stromal elements, protect malignant cells, including leukemia and myeloma cells, from drug-induced cell death. This extrinsic form of drug resistance may allow cells to survive initial drug treatment and thereby acquire a more complex, intrinsic drug-resistant phenotype. Focusing on this form of do novo drug resistance may ultimately prevent the emergence of acquired drug resistance and enhance drug therapy for hematologic malignancies.
UR - http://www.scopus.com/inward/record.url?scp=2442533725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442533725&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2004.02.001
DO - 10.1053/j.seminhematol.2004.02.001
M3 - Article
C2 - 15190509
SN - 0037-1963
VL - 41
SP - 1
EP - 5
JO - Seminars in hematology
JF - Seminars in hematology
IS - 2 SUPPL. 4
ER -